Blood test flags effective breast cancer therapies before treatment starts
A London study shows a simple liquid biopsy measuring circulating tumour DNA (ctDNA) in advanced breast cancer can predict treatment response before starting therapy and after one cycle. In 167 patients, lower ctDNA levels were associated with better outcomes, suggesting this test could guide personalized treatment and spare ineffective drugs, with trials exploring adaptive strategies and newer therapies.
